used in the treatment of schizophrenia and thus has been studied extensively (for review see Joyce and Meador-Woodruff 1997) . It is concentrated in major dopaminoceptive areas, primarily in the striatum, both in the rat and human brain (Bouthenet et al. 1987; MeadorWoodruff et al. 1991; Murray et al. 1994) . Lower concentrations of D 2 binding sites and mRNA have also been observed in various extrastriatal brain regions suggesting that the D 2 receptor plays a role in their functions (Bouthenet et al. 1987; Janowski et al. 1992; Murray et al. 1994; Meador-Woodruff et al. 1994b .
In 1990 Sokoloff and associates (Sokoloff et al. 1990 ) cloned and characterized the rat DA D 3 receptor. It has high homology with the D 2 receptor and shares many pharmacological features of the latter including high affinity for D 2 receptor antagonists clinically used as antipsychotics. It has been proposed that the D 3 receptor is involved in schizophrenia pathology and antipsychotic action (Sokoloff et al. 1990; Gurevich et al. 1997; Joyce and Meador-Woodruff 1997) , and plays a role in drugseeking behavior (Caine and Koob 1993; Staley and Mash 1996) . It has been shown that in the rodent the D 3 receptor is much less abundant than the D 2 receptor, has a restricted distribution, and exhibits a significant degree of segregation from the D 2 receptor in the nucleus accumbens (Bouthenet et al. 1991; Meador-Woodruff et al. 1991; Huang et al. 1992; Diaz et al. 1995; Le Moine and Bloch 1996) . This limited distribution suggested a specific function for the D3 receptor subtype distinct from that of the D2 receptor and related to the mesolimbic rather than nigrostriatal system. In the human brain the D 3 receptor and its mRNA appear to be more widely distributed than in the rat (Landwehrmeyer et al. 1993; Meador-Woodruff et al. 1994a Murray et al. 1994; Suzuki et al. 1998) , which may indicate a more extensive overlap of D 3 and D 2 receptors and more extensive role of the D 3 subtype in mediating actions of DA.
Most of our knowledge concerning localization of the D 2 and D 3 receptor subtypes in the human brain has been derived from experiments with in situ hybridization followed by low-resolution film autoradiography. Corresponding data on the distribution of D 2 and D 3 binding sites are often not available or have been obtained with non-selective radioligands. In this study we evaluated the distribution of D 2 and D 3 mRNA-positive neurons using non-isotopic in situ hybridization histochemistry (ISHH), which provides high cellular resolution. Systematic mapping of D 2 and D 3 receptor binding sites was used to compare the mRNA and receptor distributions. We also combined ISHH with immunochemistry to demonstrate the receptors' expression in the specific cell types and, for some regions, performed double-ISHH to detect their co-expression. This work extends previous studies of the D 2 and D 3 receptor distribution in the striatal and nigral areas and for the first time describes in detail the distribution of D 2 and D 3 binding sites and mRNAs in the basal forebrain, thalamic, hypothalamic, and amygdaloid nuclei. Our data support the hypothesis that in the human the D3 receptor is located, in addition to the limbic regions, in the sensory, motor, and association areas. The data were presented previously in their preliminary form (Gurevich and Joyce 1996) .
METHODS

Subjects and Tissue Preparation
Frozen human brain tissue was obtained from the Hospital of the University of Pennsylvania (Dr. John Trojanowski, Director of Medical Pathology). Fixed cryoprotected sections of the human brain were obtained from the brain bank at Sun Health Research Institute. The left or right frozen hemispheres of 10 normal brains (5 males, 5 females) were used. Fixed sections from 6 normal cases (3 males, 3 females) were available from the left hemisphere only. The cases had no known history of neurological, neurovascular, or psychiatric disorder. Routine gross neuropathological and microscopic histopathological examination found no abnormalities in the tissue. The mean age at death was 68.7 Ϯ 3.7 (frozen tissue) and 78.8 Ϯ 1.5 (fixed tissue), mean post-mortem interval (PMI) was 13.2 Ϯ 1.7 h (frozen tissue) and 1.8 Ϯ 0.2 h (fixed tissue). Causes of death included respiratory failure, cardiac arrest, myocardial infarction, pneumonia, and various forms of cancer. No tissue from suicide victims was used in the study. All tissue used was acquired in 1994-95. Brain hemispheres were rapidly dissected into 1-cm thick slices, cut into slabs, and frozen in isopentane on dry ice. Fixed tissue was prepared by placing 1-cm thick slices dissected from left hemispheres in 4% paraformaldehyde in 0.1 M phosphate buffer for 48 h, placed in 2% dimethylsulfoxide, 10% glycerol in 0.1 M phosphate buffer for cryoprotection for 48 h, and then transferred to the same buffer with 20% glycerol. 40 m-thick sections were cut on a freezing microtome, placed in 50% glycol, and stored at Ϫ 20 Њ C until needed. Two days before the experiment the sections were washed in phosphate buffered saline (PBS), treated with 3% H 2 O 2 /10% methanol in PBS to eliminate endogenous peroxidase activity, mounted on Vectabond (Vector Laboratories, Burlingame, CA) coated slides and air dried overnight. The next day the sections were defatted in chloroform:ethanol 1:1 overnight, rehydrated, and dried overnight before use in the experiments. Frozen sections (10-15 m thick) were cut on Leica CM1900 cryostat and mounted on Probe-On Plus slides (Fisher, Pittsburgh, PA) . The sections were fixed in 4% paraformaldehyde in PBS for 1 h at 4 Њ C, washed 3 ϫ 5 min in PBS, dehydrated in ethanols, dried, and stored at Ϫ 80 Њ C. Frozen sections were used for receptor 
In Situ Hybridization Histochemistry and Immunohistochemistry
Probe Synthesis. The cDNA probe used to label the dopamine D 2 receptor was kindly provided by Dr. Roman Artymyshyn, University of Pennsylvania. The probe, 290 bp in length corresponding to the third cytosolic loop, recognized both long and short isoforms of the D 2 receptor. The full-size cDNA for the human D 3 receptor was a gift from Dr. Gurnam Gill, Pharmacia & UpJohn. Two probes for the D 3 receptor were constructed. One was 490 bp in length corresponding to IV and V transmembrane domains and part of the third cytosolic loop. The second probe was 447 bp in length and corresponded to the third cytosolic loop and VI membrane domain. Riboprobes were generated using 33 P-(NEN, Boston, MA), digoxigenin-, or fluorescein-labeled UTP (Boehringer, Indianapolis, IN) in standard transcription reactions. Radioactive probes were phenol-chloroform purified and ethanol precipitated. Non-isotopic probes were prepared according to the manufacturer's instructions, and their concentrations were determined spectrophotometrically.
Detection of D 2 and D 3 mRNA. Before hybridization the sections were treated with proteinase K (1 g/ml) for 10 (frozen sections) or 30 (fixed sections) min at 37 Њ C, incubated in 0.1 M triethanolamine with acetic anhydride for 15 min at room temperature, rinsed in 2 ϫ SSC, dehydrated through ethanols and dried. Approximately 100 ng of digoxigenin or fluorescein-labeled or 2-5 ϫ 10 6 cpm of 33 P-labeled probes in 60 l of hybridization buffer containing 75% formamide, 50 mM Tris.HCl, 2.5 mM EDTA, 4 ϫ SSC, 10% dextran sulfate, 1 mg/ml tRNA, 1 mg/ml calf thymus DNA was used for each section. The sections were incubated for 20 h at 55ЊC.
Simultaneous Detection of D 2 and D 3 mRNAs. In double-labeling experiments the sections were hybridized with two probes, one fluorescein-and the other digoxigenin-labeled. Upon completion of hybridization the sections were rinsed in 4 ϫ SSC to remove coverslips, washed in 50% formamide/2 ϫ SSC for 15 min at 55ЊC, rinsed in 2 ϫ SSC 2 ϫ 10 min, treated with RNAse A (200 mg/ml) in 2 ϫ SSC for 1 h at 37ЊC, washed in 2 ϫ SSC 3 ϫ 15 min, in 0.5 ϫ SSC for 60 min at 55ЊC, in 0.1 ϫ SSC for 60 min at 55ЊC, and in 0.1 ϫ SSC for 10 min at room temperature. The sections were then incubated in a blocking solution containing 5% BSA and 0.3% Triton X-100 for 30 min at room temperature. Sheep antidigoxigenin antibody (Fab fragment) conjugated with alkaline phosphatase was used at a 1:1000 dilution. Sheep anti-fluorescein peroxidase-conjugated antibody (Fab fragment) (Boehringer, Indianapolis, IN) was used at a dilution of 1:200. Fixed sections were treated with 0.3% H 2 O 2 in methanol before use with peroxidase conjugated antibodies. In double-labeling experiments both antibodies were applied simultaneously. After incubation overnight at 4ЊC with the appropriate antibody, the sections were washed in PBS 3 ϫ 10 min and in the appropriate substrate buffer for another 10 min at room temperature. The sections were then placed in substrate solution with incubation for 12-72 h at 37ЊC for alkaline phosphatase and at room temperature for peroxidase. 3,3Ј-Diaminobenzidine (DAB) (Sigma, St. Louis, MO) at a 0.05% concentration was used as a substrate for peroxidase. For alkaline phosphatase a mixture of nitroblue tetrasolium (0.34 mg/ml) and 5-bromo-4-chloro-3-indolyl phosphate (0.17 mg/ml) (NBT/BCIP) (Boehringer, Indianapolis, IN) was used. Substrate solutions contained 0.2 mg/ml of levamisol to block endogenous alkaline phosphatase activity. When the color developed, the sections were washed in 10 mM Tris/50 mM EDTA (TE) buffer for 30 min at room temperature, dehydrated in ethanol, washed in xylene, and mounted with Permount. In double-labeling experiments the sections were first incubated with DAB, washed in TE for 30 min, washed in the substrate buffer, and then incubated with NBT/BCIP substrate solution. When the color developed, the sections were again washed in TE buffer, dehydrated, and mounted from xylene with Permount. For sections containing the substantia nigra the double-labeling experiments were accomplished by using one 33 P-labeled riboprobe and the one digoxigeninlabeled riboprobe. The non-isotopic probe was detected as described above, then sections were extensively washed in 1 ϫ SSC, air dried, briefly dipped in 100% ethanol, dried, covered with 1% solution of cellulose nitrate in n-amyl acetate, dried, and dipped in nuclear emulsion (Ilford, Paramus, NJ). Emulsion-covered sections were exposed for 6-10 weeks at 4ЊC, developed at 17ЊC in D-19 Kodak developer for 3 min and fixed in 30% sodium thiosulfate for 5 min. The sections were then washed in water, allowed to air dry, and mounted with Permount.
In Situ Hybridization Combined with Immunohistochemistry. When ISHH was followed by immunohistochemistry, the sections were blocked for 30 min at room temperature in PBS with 2% BSA and 0.3% Triton X-100, and incubated in PBS/1% BSA/0.3% Triton X-100 solution containing rabbit anti-choline acetyltransferase (ChAT) or anti-tyrosine hydroxylase (TH) (Chemicon, Temecula, CA) antibodies at a dilution of 1:500. The incubation was carried out overnight at 4ЊC. The ABC system (Vector Laboratories, Burlingame, CA) and AEC (Sigma, St. Louis, MO) or SG Blue (Vector Laboratories, Burlingame, CA) substrates for peroxidase were used for detection. Upon sufficient color development, the sections were washed in TE, rinsed in water, air dried overnight, and mounted with Permount. Sections containing the nucleus basalis (NBM or nucleus of the diagonal band (NDB) were hybridized with digoxigenin-labeled riboprobes for D 2 or D 3 receptors, as described above, then processed for ChAT immunohistochemistry. For sections containing the substantia nigra a 33 P-labeled riboprobe was used. After standard post-hybridization washes, the sections were directly processed for TH immunohistochemistry. Following detection of antibody, the sections were washed in 1 ϫ SSC, air dried overnight, and treated as described above.
Controls.
Respective sense riboprobes were used as a control for specificity of labeling. In double-labeling experiments control slides were also single-labeled for each mRNA species to determine the degree of changes introduced by the double-labeling procedure. With double-labeling protocols fewer cells were typically visible than with a single-labeling experiment. The reverse order of incubation in the substrate solutions (NBT/ BCIP first and DAB second) was tested to optimize the visualization conditions. Though the protocol finally adopted (fluorescein-labeled D 3 probe visualized first with DAB followed by digoxigenin-labeled D 2 probe) appeared to be superior in visual identification of double-labeled cells, the reverse order produced the same general pattern of labeling. In the experiments with ISHH followed by immunohistochemistry control slides were also run for single detection of ISHH and immunodetection, as well as control slides with primary antibody substituted with non-immune serum. We found that if immunochemical labeling was preceded by ISHH a proportion of antigenic sites appeared to be lost, which may be due to proteinase treatment employed in the ISHH protocol. The reverse order (immunochemistry first and ISHH second) usually resulted in a certain degradation of the hybridization signal and required care to ensure RNAse-free conditions during the immunohistochemical procedure. The protocol finally adopted appeared to be superior in preserving both hybridization and immunochemical signals. Adjacent sections were stained for Nissl and AChE to identify structures. A number of references were used to aid in the identification of the structures examined (Haber and Groenewegen 1989; Jones 1990; Sims and Williams 1990; Heckers et al. 1992 ). The basal ganglia structures were identified as described by Alheid et al. (1990) . The thalamic nuclei were delineated and named according to Ohye (1990) and Armstrong (1990) . The hypothalamic nuclei were delineated and named according to Saper (1990) . Identification and nomenclature of the amygdaloid nuclei were based primarily on the work of de Olmos (1990) . The dopaminergic cell groups in the midbrain were identified and described based on nomenclature given by Paxinos et al. (1990) .
Microscopy, Anatomy, and Data Analysis
RESULTS
We surveyed the distribution of D 2 and D 3 receptor binding sites and D 2 and D 3 mRNA positive neurons in the subcortical areas of the human brain including the caudate (CN), putamen (Pu), nucleus accumbens (NAC), globus pallidus (GP), ventral pallidum (VP), basal forebrain, thalamus, hypothalamus, amygdala, and substantia nigra (SN). Abbreviations used throughout the text are provided in Table 1 . Binding densities for D 2 and D 3 receptors and assessments of frequency of neurons positive for respective mRNA are summarized in Table 2 .
Basal Ganglia and Basal Forebrain
In agreement with data reported earlier (Joyce et al. 1986; Murray et al. 1994) , the concentration of D 2 receptors was found to be highest in the rostral CN and Pu, with the sites distributed evenly through the dorsoventral extent of the striatum (Table 2 and Figure 1A ). In contrast, D 3 receptors were more abundant in the NAC and ventral aspect of the rostral Pu and were concentrated in areas of dense binding giving both structures a patchy appearance (Table 2 and Figure 1B ) as reported previously (Murray et al. 1994; Gurevich et al. 1997) . Striatal concentrations of both D 2 and D 3 receptor sites tended to decline along the rostro-caudal axis of the striatum. Both D 2 and D 3 receptor sites were also present in the GP (Figure 1 ). The concentration of D 2 receptors was considerably higher in the external (GPe) as opposed to the internal segment of the GP (GPi), whereas D 3 receptor concentrations were comparable in both segments. In the GPi D 3 sites were more abundant than D 2 sites, accounting for more than 70% of combined D 2 and D 3 binding site concentration, especially at the rostral level (Table 2, Figure 1 , and Figure 2B ). The concentration of D 3 sites was also high in the rostral VP ( Figure 2A ). D 2 receptor mRNA was expressed in many neurons in the Pu, CN, and the NAC ( Figure 3A and 4A). The neurons expressing D 2 mRNA appeared to be distributed evenly over the striatum. D 3 mRNA positive neurons were also found throughout the striatum (Figure Table 1. mRNA expressing neurons in the NAC tended to appear in clusters, whereas D 2 positive neurons were distributed more evenly. D 2 and D 3 mRNA expressing cells were detected in both the GPe and GPi (Figures 3G and 3H) . In the GPe the frequency of the D 3 mRNAexpressing neurons was lower than that of D 2 mRNAexpressing neurons, whereas in the GPi frequency of each type of labeled cells appeared to be similar (Figures 3G and 3H) . D 3 mRNA positive neurons were frequently found clustered at the medial pole of the internal segment, the area that also displayed a high concentration of D 3 receptor sites ( Figures 1F and 2B ). Some neurons in the globus pallidus co-expressed D 2 and D 3 mRNA, but many appeared to be labeled only for one or the other mRNA species, most often for D 2 mRNA (Figures 4E).
In the magnocellular complex of the basal forebrain the concentration of D 2 receptor sites was higher than that of D 3 sites (Table 2 ; Figures 1C and 1D, and 2A, B) . D 2 and D 3 mRNAs were found in both vertical and horizontal subdivisions of the NDB as well as in NBM. Staining density of most cells and frequency of stained neurons appeared to be higher for D 2 than D 3 mRNA. ISHH combined with immunohistochemistry demonstrated that neurons positive for ChAT were often positive for D 2 and D 3 mRNAs (Figures 4C and D) . Doublelabeling experiments demonstrated that D 2 and D 3 mRNAs were co-expressed in 38.2 Ϯ 6.0% of labeled neurons in both nuclei ( Figure 4F ).
Thalamus and Hypothalamus
In the human thalamus we found differing patterns for the distribution of D 2 and D 3 binding sites. Moderate to low concentrations of D 2 sites were found in all thalamic nuclei (Table 1 ; Figures 1A and C) . The highest D 2 receptor concentration was found in the intralaminar nuclei, especially in the central medial nucleus (Figures 1A and C; Figure 5B ; arrows). The anterior thalamus had a slightly higher D 2 receptor concentration than most other nuclei. In the posterior thalamus the geniculate nuclei, both medial (MGN) and lateral (LGN) and ventral posterolateral nucleus possessed D 2 sites in low concentrations ( Figure 5B ). As exemplified in Figures 1B and D, D 3 receptors were also relatively abundant in the AV. Other nuclei in the rostral thalamus displayed measurable but low D 3 binding. Interestingly, D 3 binding sites were also found in the mammillo-thalamic tract (mtt), starting at its point of origin in the mammillary nuclei (MM) ( Figure 2C ) and ascending throughout the length of the tract to the AV ( Figures 1D and 2D) . The concentration of D 3 receptor sites in the tract, especially in its ventral portion, was equal to or higher than in the target structure or in the MM. With the aid of adjacent sections stained for Nissl and AChE, we took special care to distinguish between the mtt and the intralaminar nuclei, which are embedded in the internal medullary lamina of the thalamus, and confirmed that D 3 binding sites were indeed located in mtt itself. The origin of D 3 binding sites in mtt is not clear. However, the same organization of D 3 receptors in the mtt and attendant nuclei was observed in the rat brain, where D 3 receptors were present in the anterior nuclei (anterodorsal and anteromedial) of the thalamus and MM as well as in the mtt (Figure 6 ). In contrast, D 2 receptors were not found in the mtt, though present in all intralaminar nuclei contained within the internal medullary lamina of the thalamus. This suggests an important role for the D 3 receptor in regulating afferents to the anterior nuclei of the thalamus that is conserved across species. In the posterior part of the thalamus modest D 3 binding was observed in the geniculate bodies, especially in the LGN ( Figure 5C ).
Localization of D 2 and D 3 receptor mRNA expressing cells in the human thalamus generally, but not always, matched that of the respective receptor sites. Numerous D 3 as well as D 2 positive neurons were observed in the AV ( Figure 7E ). The MD was also comparatively rich in Generally D 3 mRNA-expressing neurons tended to concentrate along the midline of the thalamus, and the staining intensity was higher in the neurons close to midline than in the more laterally located cells. D 2 receptor mRNA-expressing neurons were distributed more uniformly throughout the thalamus, and their density was higher than that of D 3 mRNA-expressing neurons. Double labeling for D 2 and D 3 mRNA revealed the presence of neurons that expressed both mRNA species throughout the thalamus. They were more numerous along the midline, particularly in the AV and MD (Figures 8C and D) , where D 3 expressing neurons were more likely to be found. In the more lateral parts of the thalamus the majority of neurons solely stained for D 2 mRNA. Double-labeled neurons accounted for 31.6 Ϯ 5.3 and 20.9 Ϯ 1.0% of labeled cells in AV and MD, respectively, as opposed to 11.7 Ϯ 0.7% in the ventral anterior nucleus. D 3 mRNA could be detected in large neurons, most of which also expressed D 2 mRNA, in the lateral part of the ventral posterolateral nucleus ( Figure 8A) . A considerable number of double-labeled neurons were observed in the LGN, especially large neurons within the first layer (Table 2 ). In the upper layers of the LGN D 2 mRNA positive neurons were more frequent than double-labeled neurons (Table 2 and Figure 8F ). In the layer I of LGN double-labeled neurons represented 48.3 Ϯ 6.5% of all labeled cells, whereas in the upper layer only 22.0 Ϯ 3.8% of cells were double-labeled. Neurons selectively labeled for D 3 mRNA were encountered, albeit rarely ( Figure 8E ).
In the hypothalamus D 2 receptor sites were observed in all major areas without substantial variation in the Figures 1A and C) . In accordance with the distribution of D 2 receptor sites, neurons stained for D 2 mRNA were found in all major nuclei: periventricular, preoptic, dorsal, lateral, and posterior. The staining intensity varied from moderate to weak. The most intensely stained cells were observed in the lateral hypothalamic area and ventromedial nucleus. D 3 receptor sites were observed in all hypothalamic nuclei, but the densities were extremely low (Figures 1C and D; Figure 2) . We were only able to consistently find neurons positive for D 3 mRNA in the MM ( Figure 9A ) and lateral hypothalamic area (data not shown). It is possible that D 3 positive cells also resided in other hypothalamic areas, because the receptor sites were present, but D 3 mRNA positive neurons in this region were extremely difficult to detect.
Amygdala
As described previously (Joyce et al. 1991; Murray et al. 1994) , D 2 receptor binding sites were found in most amygdaloid nuclei, but the amygdalostriatal transitional area (AStr) and the basolateral nucleus (BL) had considerably higher concentrations of the sites than any other area (Table 1 and Figure 5E ). Within the BL higher concentrations of the D 2 sites were found in the intermediate, ventromedial, and dorsal subdivisions, while ventrolateral, and paralaminar subdivisions displayed lower concentrations. It should be noted, however, that binding densities in the basolateral nucleus varied considerably among individuals. In the central nucleus the concentration of D 2 binding sites was low, with islands of dense binding observed at the lateral border of the nucleus (Figure 5E ; arrow). D 2 binding sites were present in the lateral nucleus in very low con- (Figure 9C ), which corresponded to the region of the highest density of D 3 binding sites ( Figure 5F ), but, in contrast with the D 2 mRNA positive cells, rarely detected in other subdivisons of the BL. D 3 as well D 2 mRNA positive neurons were observed in the cortical nucleus of the amygdala, especially in its dorsal subdivision (Figure 9E ), as well as in the BM and, to a lesser extent, in the lateral nucleus. In spite of the presence of measurable concentrations of D 3 receptor sites in the amygdala, D 3 mRNA positive cells were relatively sparse, and staining intensity was generally low. However, neurons containing both mRNA species were identifiable, particularly in the BL ( Figure 8B ). Double labeled neurons accounted for 11.6 Ϯ 5.6% of all labeled cells in the dorsal and dorsolateral subdivisions of BL, but were very rare in all other areas.
Substantia Nigra and Ventral Tegmental Area
D 2 receptor sites were found in all groups of midbrain dopaminergic neurons (Table 1) . Relatively high concentrations of receptor sites were observed in the ventral tegmental area (VTA) in the paranigral (PN) and parabrachial pigmented nuclei (PBP) ( Figure 10C ). Binding in the caudal linear nucleus (CLi) was also detectable. Conversely, few, if any, D 3 sites could be seen in the Table 1. PN, PBP, or CLi ( Figure 10B ). D 3 receptor sites were detected throughout the substantia nigra pars reticulata (SNr), where D 2 sites were absent. The area of highest density of D 3 sites was located in the medial SNr. Thus, D 2 receptor binding was highest in the dorsal and ventral tiers of the substantia nigra pars compacta (SNc) but D 3 labeling was highest in the SNr (Figures 10B and C) . Prevalence of D 3 rather than D 2 receptors in SNr is further illustrated in Figures 1A and B , which shows higher ratio of D 3 to D 2 binding sites in the rostral part of SNr.
The relative segregation of the D 3 from D 2 receptor subtype was not as clearly evident for the neurons expressing the respective mRNAs. D 2 receptor mRNA was detected in the large neuromelanin containing neurons of the SNc as well as in all components of the VTA using both isotopic ( Figure 10D ) and nonisotopic probes ( Figures 11A-C) . The PN (Figures 10D and 11A ) as well as a considerable proportion of neurons in the PBP ( Figures 10D and 11B ) appeared heavily labeled for D 2 mRNA. The CLi, which is sparsely populated, displayed a number of D 2 mRNA-negative as well as D 2 -positive cells (Figures 10D and 11C ). Many neurons in the SN labeled for D 2 mRNA were TH-positive ( Figure  11D ). A few TH-negative cells that stained for D 2 mRNA were observed. D 3 mRNA was present in the large cells of the SNc, often co-localizing with D 2 mRNA ( Figures  10B and 11E ). Many neurons stained for D 3 mRNA were also TH-positive ( Figure 11F ). However, many cells were detected in SNc that contained D 2 but not D 3 mRNA. In the SNr, though, a number of predominantly small non-pigmented cells were single-labeled for D 3 mRNA. Only occasional D 3 mRNA positive cells were observed in the PBP and PN.
DISCUSSION
The present study demonstrates the widespread distribution of both D 2 and D 3 receptor subtypes in the human brain. D 2 binding sites and D 2 mRNA positive neurons were widely distributed in the subcortical regions. As illustrated in Table 2 and Figure 12 , the D 3 receptor was found in higher concentrations in a limited number of brain areas closely connected anatomically and functionally. In agreement with previous reports, we found that the D 2 receptors and mRNA were the most abundant in the dorsal CN and Pu (Joyce et al. 1991; Huntley et al. 1992; Murray et al. 1994; Meador-Woodruff et al. 1996) , whereas D 3 receptor sites and mRNA were enriched in the ventral Pu and NAC, often in dense patches of binding and clusters of D 3 mRNA positive neurons, (Landwehrmeyer et al. 1993; Herroelen et al. 1994; Murray et al. 1994; Meador-Woodruff et al. 1996; Gurevich et al. 1997; Suzuki et al. 1998) . NAC, which has the highest D 3 receptor concentration and number of D 3 mRNA positive neurons of all brain areas, projects primarily to the VP, medial part of the GPi and SNr (Haber et al. 1985; Haber 1994a, 1994b) , all regions enriched with the D 3 receptor and D 3 mRNA positive neurons. This is interesting, because cell morphology, connections, and neurochemical and physiological characteristics of the GPi and SNr are very similar Yelnik et al. 1987) . Though these two structures do not appear to be derived from the same developmental anlage ), they may be exposed to common developmental regulatory influences resulting in a higher level of expression of the D 3 receptor, which, in its turn, may contribute to unification of the structures, along with VP, into one functional system thus modulating the output of the limbic striatum. However, in the human brain, in contrast with the rat, distributions of D 2 and D 3 binding sites in the striatal areas were overlapping to a considerable degree suggesting that both subtypes mediate dopaminergic input in motor and limbic striatal areas. In pallidal and basal forebrain neurons both mRNA species were often detected, which may indicate functional importance of convergence of signals mediated by the two subtypes.
The thalamus and hypothalamus have not received much attention with regard to their dopaminergic in- Table 1. nervation and expression of DA receptors, in part due to relatively low levels of all DA receptors. D 2 receptor sites in these regions were previously identified using membrane binding and autoradiography (Janowski et al. 1992; Kessler et al. 1993) , and D 2 mRNA has been identified in the nonhuman primate (Choi et al. 1995) . A recent report demonstrated the presence of D3 receptor mRNA in the human thalamus (Suzuki et al. 1998) . Dopaminergic innervation to the rat LGB (Papadopoulus and Parnavelas 1990) and the human thalamus (Malais et al. 1990; Oke et al. 1992 ) has been demonstrated, though its sources are unknown. We have Table 1. shown D 2 and D 3 receptor sites and mRNA in many thalamic nuclei and throughout the hypothalamus of the human brain, though at considerably lower levels than in the striatum (Table 2 and Figure 12 ). In most thalamic areas the presence of D 2 or D 3 receptor sites coincided with the presence of their respective mRNA indicating that thalamic neurons are capable of synthesizing the receptor proteins. The most noticeable difference in distribution of D 2 and D 3 binding sites was the presence of a relatively high concentration of D 2 receptor sites in most intralaminar nuclei, which had little or no D 3 binding, and, in contrast, the presence of D 3 sites in the mtt, which contained no D 2 sites. The AV appears to represent a major site of interaction of the D 2 and D 3 receptors, because it possesses both types of binding sites in comparable concentrations as well as neurons expressing one or both mRNA species. The AV receives a nigrothalamic innervation from the SNr, a region of relatively higher expression of D 3 than D 2 receptors, via GABAergic nigrothalamic pathway (Ilinsky et al. 1985; Kultas-Ilinsky and Ilinsky 1990) , which may be originating from non-dopaminergic D 3 mRNA positive neurons frequently observed in SNr. The AV also receives massive projections from the MM through the mtt, the former enriched with D 3 mRNA and the latter with binding sites. Although functions of the AV remain little understood, it has been implicated in mechanisms of memory and attention (von Cramon et al. 1985) . Its connections with the prefrontal, temporal, cingulate, and entorhinal cortex and hippocampal formation (for review see Armstrong 1990) suggest its importance for processing of information within the limbic circuit. Relative enlargement of the human AV comparing to other antropoids (Armstrong 1986 ) implies its involvement in specific complex aspects of behavior. Among sensory thalamic nuclei, the LGB, and to a lesser degree, the MGB possess D 2 and D 3 receptor binding sites and both mRNA species. Recent data have indicated the presence of dopaminergic fibers (Papadopoulus and Parnavelas 1990) and DA receptors (Bouthenet et al. 1987; Huang et al. 1992) in the rat LGB, and D 3 receptor mRNA in the human LGB (Suzuki et al. 1998 ). In the rat, neurons of the LGB respond to application of D 2 agonists by increased baseline activity, an effect that was reversible by specific D 2 antagonists (Albrecht et al. 1996) . In both nuclei D 3 and D 2 mRNA co-localize to a considerable proportion of neurons in magnocellular laminae 1 and 2, whereas in upper laminae D 2 mRNA positive neurons predominate. Principal auditory, visual, and somatosensory information to the cortex passes through the ventral posterior and geniculate nuclei. Complex association pathways involve orbitofrontal and dorsolateral prefrontal cortices and their projections from the anterior and medial nuclei of the thalamus (Groenewegen et al. 1990) . Investigators have proposed that in schizophrenia there are disturbances in the filtering of sensory signals in these thalamo-cortical pathways (Carlsson and Carlsson 1990) . These data suggest the modulatory role of the dopaminergic system and D 2 -like receptors not only in the limbic but also sensory thalamic nuclei, which may be particularly important for pathophysiology of schizophrenia and regulation of psychotic symptoms by DA antagonists.
We had previously described the presence of D 2 and D 3 receptor sites in the basal forebrain and amygdala (Murray et al. 1994 ). Concentration of D 2 receptors and mRNA exceeds that of D 3 receptor in both NBM and NDB. The predominant phenotype of neurons expressing either mRNA species appears to be cholinergic, and many of them co-express D 2 and D 3 mRNAs. The D 3 receptor was present in all amygdaloid nuclei at low levels and was more abundant in the magnocellular dorsolateral and dorsal subdivisions of the BL. The D 2 receptor was particularly abundant in the AStr and BL comparing to all other amygdaloid areas. Some of the large neurons of the dorso-lateral BL co-expressed D 2 and D 3 mRNA. The cholinergic neurons of the NBM and NDB and the amygdaloid nuclei, particularly the central, basal, and lateral nuclei, are provided with Table 1. dopaminergic innervation from the VTA and medial components of the SN (Sadikot and Parent 1990; Takada 1990; Gaykema and Zaborszky 1996; Zaborszky and Cullianan 1996) . This may be important in some of the cognitive difficulties associated with damage to the mesolimbic DA system in Parkinson disease (Torack and Morris 1988) , perhaps through modulation of the cholinergic system innervating the cortex (Zaborszky et al. 1993) . The amygdala has long been recognized as playing a role in emotional and affective experiences (Aggleton 1992) . The amygdala sends extensive input to the ventral striatum (Zahm and Brog 1992; Kunishio and Haber 1994) (Joyce et al. 1993 ) suggesting a region-specific dopaminergic vulnerability that may underlie some of the affective disturbances accompanying cognitive impairment in this disorder (Bungener et al. 1996; Cadieux and Greve 1997) .
Dopamine D 2 and D 3 receptors are believed to be expressed in dopaminergic neurons of the midbrain (Bouthenet et al. 1991; Diaz et al. 1995; MeadorWoodruff et al. 1994a) , where they are thought to act as autoreceptors (Rivet et al. 1994; Nissbrandt et al. 1995) . Our data demonstrating both D 2 receptor sites and mRNA in TH-positive neurons of the SNc and SNr are consistent with these findings. The D 3 receptor predominates in the rostral SNr, whereas in the SNc the D 2 receptor concentration exceeds that of the D 3 receptors. One particularly important difference with the rat is that D 3 receptors are virtually absent in the PN, CLi, and PBP that together comprise the VTA. This contrasts with studies in the rat where D 3 mRNA is evident in the VTA, SNr and pars lateralis . Although D 2 mRNA is reported to be present in the rat VTA, one report for the human has indicated a virtual absence there of D 2 mRNA expressing cells (MeadorWoodruff et al. 1994a) . However, in the present study we found both D 2 receptor sites and mRNA in all dopaminergic cell groups of the midbrain, including the VTA. Hurd et al. (1994) have also observed D 2 receptor mRNA in the VTA, but at levels significantly lower than the SN. The reason for this discrepancy between the results of Meador-Woodruff and associates (1994a) and our work is unclear. The concentration of D 2 receptor sites and mRNA expression in the CLi in our material was not high, and we observed many D 2 negative cells. Nonetheless, D 2 receptor sites and mRNA were clearly detected in the VTA, especially in the PN, as well as in SN. We conclude that, similarly to the rat brain, in the human brain the D 2 (but probably not D 3 ) receptor plays an autoreceptor role in both dopaminergic cell groups.
The present study demonstrates that in the human brain many D 3 mRNA positive neurons also express D 2 mRNA. The combined evidence of the mRNAs' coexpression and overlap in the distribution of the receptor sites suggests that in many areas a considerable proportion of neurons co-express functional D 2 and D 3 receptors. This proportion varies among areas depending largely on the concentration of the more rare D 3 mRNA. In the areas rich in D 3 receptors and mRNA, cells double-labeled for D 2 and D 3 mRNA predominate, with only occasional single-labeled D 3 mRNA positive neurons. Such areas include the basal forebrain, LGN, medial part of the AV and MD of the thalamus, SNc and SNr. By contrast, in the majority of brain areas D 2 mRNA positive neurons far outnumber D 3 mRNA positive neurons, and single-labeled D 2 mRNA positive neurons are frequently observed. Several technical considerations, however, are important for the interpretation of these results. In our double-labeling experiments positive detection of both mRNA species was emphasized. Detection of both species is obviously facilitated when both mRNAs are present at similar levels. In cells that contain one mRNA in considerably higher concentration than the other the low-abundance mRNA may not be observed. This is particularly a problem for D 3 receptor mRNA because it is usually present at low levels compared to D 2 mRNA. Thus, some neurons that have been identified as solely expressing D 2 mRNa may have also expressed D 3 mRNA in concentrations near or below our level of detection. In view of these constraints, positive double-labeling of D 2 and D 3 mRNA in the same cells may be viewed with a fairly high degree of confidence, but the failure to observe double-labeling should be interpreted with caution. In addition, the method of double-ISHH used in this study is sensitive to cell size, shape, call density, and subcellular mRNA localization. It is particularly suitable for large cells or cells where the two mRNAs are spatially segregated subcellularly. In some brain areas comprised of relatively small cells such as Pu, CN, NAC, the labels were impossible to detect reliably in the same cell because they masked each other. The conclusions we can most reliably draw are, therefore, that 1) in most regions in the forebrain D 2 receptor mRNA is present at much higher levels than D 3 receptor mRNA; 2) in a few regions of the forebrain D 3 receptor mRNA predominates; and 3) D 2 and D 3 receptor mRNA are often co-expressed in cells, particularly in areas where D 3 mRNA expression is abundant.
CONCLUSION
Based on studies in the rat, Sokoloff and associates (Sokoloff et al. 1990 ; Sokoloff and Schwartz 1995) have made the valuable suggestion that the D 3 receptor is a particularly important target for antipsychotics in the mesolimbic DA system. The present study in the human demonstrates that the distribution of D 3 receptors and D 3 mRNA-bearing neurons is consistent with relative segregation of the D 3 subtype to the limbic striatum as well as it primary and secondary targets and many sources of its afferents. The nucleus accumbens and adjacent ventral putamen, referred to as the ventral or limbic striatum, exhibit the highest expression of D 3 receptor binding sites and corresponding levels of D 3 mRNA. These regions are the targets of the mesolimbic DA system receiving input from the medial and dorsal components of the SN (Jimenez-Castellanos and Graybiel 1987; Lynd-Balta and Haber 1994a; Haber and Fudge 1997) . Additional sources of input to the limbic striatum include regions enriched in D 3 receptors such as the anterior nuclei of the thalamus and NBM. The ventral striatum projects primarily to the VP, the most medial part of the GPi and SNr (Haber et al. 1985; Lynd-Balta and Haber 1994a) , which are also enriched with D 3 receptors and D 3 mRNA positive neurons. These regions provide input to the anterior nuclei of the thalamus (Groenewegen et al. 1990 ). The AV of the thalamus, which exhibits the highest expression of D 3 receptors within the thalamus, receives a nigrothalamic GABAergic innervation from the SNr (Ilinsky et al. 1985) , a region of relatively higher expression of D 3 and D 2 receptors. This provides multiple sites at which drugs such as antipsychotics might act to regulate activity in the "limbic" loop via interaction with the D 3 receptor. However, in contrast with the rat, in the human brain the D 3 receptor is also expressed at high levels in the motor striatum. Other brain regions thought to be involved in sensory (sensory thalamic nuclei), hormonal (mmt) and association (amygdala) functions also express the D 3 receptor, often co-expressed with the D 2 receptor.
The extensive co-localization of D 2 and D 3 receptors in human forebrain raises a question about the functional significance of the simultaneous presence of pharmacologically similar DA receptors in the same cell. As has been proposed Sokoloff and Schwartz 1995) , the significantly higher affinity of the D 3 receptor for DA may enable it to serve in vivo as an extrasynaptic receptor responding to low concentrations of DA at distances remote from the point of DA release. Conversely, the D 2 receptor with its low affinity to DA is likely to respond to high synaptic concentrations of DA. Thus, brain areas with relatively high densities of D 3 receptors may be under tonic regulatory influence of the brain dopaminergic system, even if the dopaminergic innervation is sparse. D 2 and D 3 receptors may elicit opposing responses in neurons Lévesque et al. 1995; Surmeier et al. 1996) , and may respond differently to loss of DA or antipsychotic treatment (reviewed in Joyce and Meador-Woodruff 1997) . Our data provide initial insight into details of distribution and co-expression of DA D 2 and D 3 receptors in the human brain. Intricate interplay of signaling by related but not identical DA receptors in different brain areas and individual neurons remains to be elucidated. Perhaps, circuits with high D 3 receptor expression and other functionally connected systems with predominance of the D 2 receptor provide different target systems for DA antagonists in regulation of psychotic symptoms.
